The source did not report clinical renal endpoints or a 24-month cohort; this heading instead anchors a focused discussion of how lipid droplets function as a metabolic switch that determines macrophage resolution versus persistent inflammation. Macrophages store neutral lipids within LDs composed of a single phospholipid monolayer and a coat of regulatory proteins; this architecture protects cells from free-cholesterol and fatty-acid toxicity while simultaneously shaping immune signaling. The authors reported that LD behavior is context-dependent: in early lesions droplet formation can be cytoprotective, but when turnover and efflux fail, droplets mark maladaptive lipid burden that impairs clearance.
Investigators described a neutral-lipase relay—ATGL➔HSL➔MAGL—that sets the rate of triacylglycerol mobilization from droplets, with ATGL controlling the initial entry into the relay via its co-activator ABHD5/CGI-58. In parallel, a cholesterol-ester arm (ACAT1/SOAT1 esterification; NCEH1/LAL hydrolysis) defines free-cholesterol homeostasis and thereby the ER-stress threshold that affects phagosome closure. Coat proteins such as PLIN2 and PLIN3 gate lipase access to the droplet core. The authors noted that several of these enzymes are structurally characterized and thus potentially druggable, but they emphasized that many available inhibitors are tool-grade. They reported specific translational concerns: global activation of neutral lipolysis risks elevating circulating free fatty acids and creating off-target lipotoxicity, and inflammatory impairment of ABCA1/ABCG1-mediated efflux may render such flux harmful rather than reparative.
The review team observed that pro-inflammatory stimuli—IFNγ and TLR ligands—push macrophages from oxidative phosphorylation toward glycolysis. Inducible nitric oxide synthase (iNOS) activity produces NO, which interrupts the TCA cycle (via aconitase 2 targeting) and impairs mitochondrial fatty-acid oxidation. NO also promotes degradation of LXRα, downregulating ABCA1 and suppressing cholesterol efflux. Because LXR co-induces MerTK and ABCA1, NO-driven LXRα loss simultaneously compromises recognition and efflux. The authors argued that LD accumulation is frequently a consequence and marker of disrupted lipid homeostasis rather than an independent causal factor, but that accumulation does exert downstream functional effects on macrophages.
Recognition. The source notes MerTK as a central apoptotic-cell receptor. Hypercholesterolemia and oxidized phospholipids activate ADAM17, which cleaves MerTK to release soluble Mer; soluble Mer reduces surface MerTK and competes with remaining receptor function, suppressing efferocytosis and pro-resolving mediator biosynthesis. Plasma soluble Mer is elevated in active systemic lupus erythematosus; the authors linked this observation to defective recognition in autoimmune activity.
Engulfment. LDs are mechanically distinct organelles that can displace apical actomyosin structures required for cup formation. The review cited experiments where mechanical compression or stretching reversed phagocytic suppression, implying a tunable biophysical constraint rather than an irreversible defect. Excess free cholesterol can inhibit ACAT1, impair esterification, and amplify ER stress. ER-stress signaling via ATF4 upregulates TRIB3 and downregulates Rab27a, delaying phagosome closure. The review team also reported that LD biogenesis consumes ER membrane and may perturb RAC1 translocation and Rho-family GTPase activity required for actin remodeling at the cup.
Digestion and lipophagy. After engulfment, lysosomal processing and lipophagy deliver droplet lipids to lysosomal acid lipase for hydrolysis to free cholesterol and fatty acids that feed ABCA1-mediated efflux or β-oxidation. Chronic lipid loading impairs autophagy; Atg5 deficiency was reported to promote inflammasome activation, oxidative stress, and defective efferocytosis. The authors concluded that digestion failure completes a self-reinforcing loop linking lipid burden to sustained inflammation.
The authors argued that recognition, actin-driven cup formation, and lysosomal digestion form a conserved core across efferocytosis and host-defense phagocytosis. LD-lipolysis machinery may therefore influence bacterial and fungal uptake as well as apoptotic clearance. Membrane supply is a common bottleneck: engulfing large particles requires surface-area expansion that can draw on mobilizable lipid stores. When lipolysis is blocked and lipids are sequestered as inert neutral lipid, phagocytes may become substrate-limited for cup closure. Chronic lipid accumulation also impairs LC3-associated phagocytosis (LAP) and autophagy, which the authors linked to reduced microbial killing in foam cells and lipid-laden macrophages. They further described paracrine effects: macrophages can transfer lipids and lipid-handling proteins to neighboring immune cells, suppressing effector programs such as NK-cell IFNγ production.
The review identified several druggable nodes—neutral lipases, lysosomal enzymes, ACAT1/SOAT1—but stressed practical barriers. Current inhibitors for key neutral lipases (for example, the ATGL inhibitor Atglistatin and the HSL inhibitor BAY 59-9435) are described as tool-grade in the source, and investigators warned that systemic modulation could raise circulating free fatty acids and cause off-target lipotoxicity. The authors proposed that macrophage-selective delivery or tissue-restricted approaches will be required to harness the lipase relay therapeutically. They reported HSL as an experimental example where activity supports efficient efferocytosis and an M2-like phenotype; loss of HSL shifts macrophages toward a pro-inflammatory, clearance-deficient state.
Remaining gaps documented by the authors include limited characterization of LD–efferocytosis interactions across diverse tissue niches and macrophage ontogenies, a need to define which droplet coat proteins and lipases are causal versus correlative in specific contexts, and a notable omission in most work of systemic control mechanisms: the sympathetic nervous system and catecholamine-driven β-adrenergic activation of the Gs–cAMP–PKA axis were flagged as likely physiological regulators of neutral lipolysis yet remain understudied in this setting. The source did not report clinical trials, dosing, safety data, or specific patient-population results. Preclinical druggability exists, but translation requires macrophage-selective strategies and further tissue-specific mechanistic study.